EOAI3402143

CAS No. 1699750-95-2

EOAI3402143( Deubiquitinase inhibitor G9 | EOAI 3402143 )

Catalog No. M12594 CAS No. 1699750-95-2

EOAI3402143 (Deubiquitinase inhibitor G9, EOAI 3402143) is a novel covalent deubiquitinase Usp9x/Usp24 inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 75 In Stock
10MG 123 In Stock
25MG 222 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    EOAI3402143
  • Note
    Research use only, not for human use.
  • Brief Description
    EOAI3402143 (Deubiquitinase inhibitor G9, EOAI 3402143) is a novel covalent deubiquitinase Usp9x/Usp24 inhibitor.
  • Description
    EOAI3402143 (Deubiquitinase inhibitor G9, EOAI 3402143) is a novel covalent deubiquitinase Usp9x/Usp24 inhibitor with increased aqueous solubility and greater cellular Usp9x inhibitory activity than WP1130; displays nM apoptotic activity against other myeloma cell lines and diffuse large B-cell lymphomas cells; increases tumor cell apoptosis, and fully blocks or regresses myeloma tumors in mice; also inhibis Usp5.
  • In Vitro
    EOAI3402143 retains potent Usp9x and Usp5 inhibitory activity. EOAI3402143 dose-dependently inhibits Usp9x and Usp24 activity, increases tumor cell apoptosis. Treatment of UM-2, UM-6, UM-16, and UM-76 with Usp9x inhibitor EOAI3402143 (G9) dose-dependently suppresses cell survival, while 600 nM of EOAI3402143 completely suppresses UM-2 3D colony growth when compared to untreated vehicle controls.
  • In Vivo
    To examine this potential, the effect of EOAI3402143 (G9) treatment is investigated on human MIAPACA2 tumor xenografts. Human MIAPACA2 cells are injected subcutaneously into NSG mice. Primary tumor development is monitored by caliper measurements, and once measurable, mice are separated into two groups and are treated with either vehicle control (PEG300/DMSO) or G9 at 15 mg/kg. Tumor growth, animal weight, behavior, and mobility are monitored during treatment. In parallel, murine 8041 tumors are also established and subjected to similar G9 treatment and tumor monitoring regimen as the human MIAPACA2 xenografts. Consistent with the in vitro findings, Usp9x inhibition results in the suppression of tumor growth in human tumor xenografts, but any significant effect on the growth of 8041 tumors xenografts is not observed, although the Usp9x activity is inhibited effectively by EOAI3402143 treatment in both human MIAPACA2 and mouse 8041 xenograft tumors.
  • Synonyms
    Deubiquitinase inhibitor G9 | EOAI 3402143
  • Pathway
    Proteasome/Ubiquitin
  • Target
    DUB
  • Recptor
    DUB
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1699750-95-2
  • Formula Weight
    503.424
  • Molecular Formula
    C25H28Cl2N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 50 mg/mL 99.32 mM; H2O : < 0.1 mg/mL
  • SMILES
    CCCC(C1=CC=C(C=C1)OCCN2CCOCC2)NC(=O)C(=CC3=C(C=CC(=N3)Cl)Cl)C#N
  • Chemical Name
    (E)-2-cyano-3-(3,6-dichloropyridin-2-yl)-N-(1-(4-(2-morpholinoethoxy)phenyl)butyl)acrylamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Peterson LF, et al. Blood. 2015 Jun 4;125(23):3588-97. 2. Potu H, et al. Oncotarget. 2014 Jul 30;5(14):5559-69.
molnova catalog
related products
  • USP25 and 28 inhibit...

    USP25 and 28 inhibitor AZ-2 is a?potent, selective, dual USP25/28 inhibitor with IC50 of 0.9/0.9 uM, respectively.

  • FT-671

    FT-671 is a novel potent, specific, non-covalent USP7 inhibitor with Kd of 65 nM (USP7 catalytic domain).

  • P22074

    P22074 is a USP7 inhibitor. It is not an active antagonist like its halogenated related compounds. p22074 has antitumour activity.